Meta-Analysis and Trial Sequential Analysis of the Efficacy of TCM in the Treatment of Coronary Heart Disease and TG-Lowering Level Based on the Theory of"Spleen Failing to Disperse Essence and Combined Phlegm and Stasis"Combined with Western Medicine
- VernacularTitle:基于"脾不散精,痰瘀互结"理论组方联合西药治疗冠心病疗效及降TG水平的Meta分析与试验序贯分析
- Author:
Zhiqiang XIAO
1
;
Xinjun ZHANG
1
;
Ning GU
1
Author Information
- Publication Type:Journal Article
- Keywords: Coronary heart disease; Hypertriglyceridemia; Spleen failing to disperse essence and combined phlegm and stasis; Meta-analysis; Trial sequential analysis; GRADE
- From: World Science and Technology-Modernization of Traditional Chinese Medicine 2025;27(5):1312-1325
- CountryChina
- Language:Chinese
- Abstract: Objective To analyze the efficacy and safety of the traditional Chinese medicine(TCM)in the treatment of treating coronary heart disease and their effects on TG levels of patients with dyslipidemia based on the theory of"Spleen failing to disperse essence and combined phlegm and stasis"combined with Western medicine.Methods Eight different electronic databases were searched to include randomized controlled trials(RCTs)of the TCM based on the theory of"Spleen failing to disperse essence and combined phlegm and stasis"for CHD complicated with dyslipidemias published from inception to November 2024.Literature screening and data extraction were performed based on the inclusion and exclusion criteria.Meta-analysis was performed by RevMan 5.4.The GRADE system and TSA 0.9.5.10 Beta were adopted to evaluate the certainty and conclusiveness of the evidence.Results A total of 30 RCTs involving 2798 subjects were included.There were 1402 subjects in the experimental group and 1396 subjects in the control group.Meta-analysis showed that the group of Huatan Quyu therapy was effective in improving the clinical efficacy(RR=1.26,95%CI[1.19,1.33],P<0.00001),angina symptoms(RR=1.25,95%CI[1.14,1.37],P<0.00001),electrocardiogram efficacy(RR=1.27,95%CI[1.17,1.39],P<0.00001),and TCM symptom efficacy(RR=1.32,95%CI[1.23,1.42],P<0.00001).Additionally,TG levels(WMD=-0.44,95%CI[-0.52,-0.36],P<0.00001)and hs-CRP levels(WMD=-2.80,95%CI[-3.15,-2.45],P<0.00001)decreased.Concerning hemorheology,Huatan Quyu therapy effectively reduced WBV(WMD=-1.34,95%CI[-1.65,-1.02],P<0.00001)、PV(WMD=-0.44,95%CI[-0.45,-0.43],P<0.00001)and FIB(WMD=-0.46,95%CI[-0.75,-0.18],P=0.001).In terms of safety,19 studies reported the adverse reactions in detail,but the severity was mild and symptoms disappeared after treatment.TSA showed that the cumulative Z-curve of the clinical efficacy crossed the traditional threshold and TSA threshold,which further affirmed the clinical efficacy.The GRADE graded the evidence of the above outcome indicators as moderate or low.Conclusion TCM based on the theory of"Spleen failing to disperse essence and combined phlegm and stasis"may be effective and safe in the treatment of patients with CHD and lowering TG levels in dyslipidemic patients.Since the quality of the literature included in this study was generally low,there is an urgent need for more RCTs with high quality,low bias risk and sufficient sample size to validate the above conclusions.
